Epigenetic control of variation and stochasticity in metabolic disease

Panzeri, Ilaria; Pospisilik, John Andrew

doi:10.1016/j.molmet.2018.05.010

アイテム詳細

登録内容を編集ファイル形式で保存

一時保存へ追加

タグ情報を表示リリース履歴を表示詳細要約

公開

学術論文

Epigenetic control of variation and stochasticity in metabolic disease

MPS-Authors

Panzeri, Ilaria
Department of Epigenetics, Max Planck Institute of Immunobiology and Epigenetics, Max Planck Society;

/persons/resource/persons198873

Pospisilik, John Andrew
Department of Epigenetics, Max Planck Institute of Immunobiology and Epigenetics, Max Planck Society;

External Resource

There are no locators available

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

フルテキスト (公開)

公開されているフルテキストはありません

付随資料 (公開)

There is no public supplementary material available

引用

Panzeri, I., & Pospisilik, J. A. (2018). Epigenetic control of variation and stochasticity in metabolic disease. Molecular Metabolism, 14, 26-38. doi:10.1016/j.molmet.2018.05.010.

引用: https://hdl.handle.net/21.11116/0000-0002-4866-B

要旨

BACKGROUND:
The alarming rise of obesity and its associated comorbidities represents a medical burden and a major global health and economic issue. Understanding etiological mechanisms underpinning susceptibility and therapeutic response is of primary importance. Obesity, diabetes, and metabolic diseases are complex trait disorders with only partial genetic heritability, indicating important roles for environmental programing and epigenetic effects.

SCOPE OF THE REVIEW:
We will highlight some of the reasons for the scarce predictability of metabolic diseases. We will outline how genetic variants generate phenotypic variation in disease susceptibility across populations. We will then focus on recent conclusions about epigenetic mechanisms playing a fundamental role in increasing variability and subsequently disease triggering.

MAJOR CONCLUSIONS:
Currently, we are unable to predict or mechanistically define how "missing heritability" drives disease. Unravelling this black box of regulatory processes will allow us to move towards a truly personalized and precision medicine.